Login / Signup

Initial COVID-19 severity influenced by SARS-CoV-2-specific T cells imprints T-cell memory and inversely affects reinfection.

Gang YangJinpeng CaoJian QinXinyue MeiShidong DengYingjiao XiaJun ZhaoJunxiang WangTao LuanDaxiang ChenPeiyu HuangCheng ChenXi SunQi LuoJie SuYunhui ZhangNanshan ZhongZhongfang Wang
Published in: Signal transduction and targeted therapy (2024)
The immunoprotective components control COVID-19 disease severity, as well as long-term adaptive immunity maintenance and subsequent reinfection risk discrepancies across initial COVID-19 severity, remain unclarified. Here, we longitudinally analyzed SARS-CoV-2-specific immune effectors during the acute infection and convalescent phases of 165 patients with COVID-19 categorized by severity. We found that early and robust SARS-CoV-2-specific CD4 + and CD8 + T cell responses ameliorate disease progression and shortened hospital stay, while delayed and attenuated virus-specific CD8 + T cell responses are prominent severe COVID-19 features. Delayed antiviral antibody generation rather than titer level associates with severe outcomes. Conversely, initial COVID-19 severity imprints the long-term maintenance of SARS-CoV-2-specific adaptive immunity, demonstrating that severe convalescents exhibited more sustained virus-specific antibodies and memory T cell responses compared to mild/moderate counterparts. Moreover, initial COVID-19 severity inversely correlates with SARS-CoV-2 reinfection risk. Overall, our study unravels the complicated interaction between temporal characteristics of virus-specific T cell responses and COVID-19 severity to guide future SARS-CoV-2 wave management.
Keyphrases
  • sars cov
  • respiratory syndrome coronavirus
  • coronavirus disease
  • healthcare
  • emergency department
  • type diabetes
  • working memory
  • drug induced
  • liver failure
  • intensive care unit
  • adverse drug